The Consumer Healthcare Products Association announced its first-ever Regulatory & Scientific Affairs Career Achievement Award winners at its annual Regulatory, Scientific & Quality conference in Bethesda, Maryland.
Created to honor individuals maintaining a career of exceptional service and contributions within the consumer healthcare products industry, the establishment of this award and its inaugural recipients was announced by Lauren Quinn, vice president of U.S. regulatory affairs at Haleon, formerly GSK, and chair of CHPA’s Regulatory & Scientific Affairs Committee.
Recipients of the 2022 Regulatory & Scientific Affairs Career Achievement Award include William Cooley, independent consultant, who was previously with Procter & Gamble, and Sue James, vice president and head of global regulatory affairs at Haleon.
[Read more: CHPA welcomes new members and officers]
“I am very excited that CHPA is recognizing the contributions of the scientific community to innovation in self-care products,” said CHPA’s senior vice president of regulatory and scientific affairs, Barbara Kochanowski. “These inaugural recipients have exceptional careers where they have improved public health through innovation in regulatory science, including influencing our regulatory framework and prescription-to-nonprescription switches of OTC medicines. They also have grown regulatory expertise in our industry by serving as role models and mentors to many.”
The Regulatory & Scientific Affairs Career Achievement Award recognizes individuals whose outstanding service and contributions to the consumer healthcare products industry have created long-lasting impacts in support of public health.
Cooley’s career in the self-care industry spans more than 40 years, first at Procter & Gamble and then as an independent consultant. During this time, Cooley has made significant impacts on our industry through his leadership of several oral care teams, which helped build the oral care regulatory framework and, more broadly, the Over-The-Counter Monograph system we have today.
With a career consisting of 40 years in the self-care industry, 23 of which were spent leading global regulatory affairs at GSK, now Haleon, James’s expertise in OTC regulatory issues, especially Rx-to-OTC switch, has resulted in increased consumer access to many first-in-class products.
In some cases, use of ancillary educational materials helped set a precedent for Nonprescription Drug Safe Use Regulatory Expansion, now known as Additional Condition for Nonprescription Use. Additionally, her service to the self-care industry through leadership positions in the Regulatory Affairs Professional Society and the Global Self-Care Federation has ensured the reapplication of best practices.